Current trends in functional imaging of pheochromocytomas and paragangliomas

Annals of the New York Academy of Sciences

Volumn 1073, Issue , 2006, Pages 374-382

  Shulkin, Barry L ^a   Ilias, Ioannis ^b   Sisson, James C ^c   Pacak, Karel ^d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Nuclear medicine methods; Pheochromocytoma diagnosis; Positron emission tomography; Radionuclide imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; CATECHOLAMINE;

COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; HUMAN; ISOTOPE LABELING; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 33845494538     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1353.041     Document Type: Conference Paper

References (37)

1. NEUMANN, H.P. et al. 2002. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346: 1459-1466.
2. MUNDSCHENK, J. et al. 1998. Malignant pheochromocytoma. Exp. Clin. Endocrinol. Diabetes 106: 373-376.
3. AVERBUCH, S.D. et al. 1988. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann. Intern. Med. 109: 267-273.
4. PROYE, C. et al. 1992. High incidence of malignant pheochromocytoma in a surgical unit: 26 cases out of 100 patients operated from 1971 to 1991. J. Endocrinol. Invest. 15: 651-663.
5. TISCHLER, A. 1998. The adrenal medulla and extra-adrenal paraganglia. In Functional Endocrine Pathology. K. Kovacs & S. Asa, Eds.: 550-595. Blackwell. Oxford.
6. GOLDSTEIN, R.E. et al. 1999. Clinical experience over 48 years with pheochromocytoma. Ann. Surg. 229: 755-766.
7. SCHULZ, C. et al. 2004. Principles of catecholamine biosynthesis, metabolism and release. Front. Horm. Res. 31: 1-25.
8. 131I]iodobenzylguanidine. J. Nucl. Med. 21: 349-353.
9. SISSON, J.C. et al. 1981. Scintigraphic localization of pheochromocytoma. N. Engl. J. Med. 305: 12-17.
10. SHULKIN, B. et al. 1986. 123I-4-Amino-3-iodobenzylguanidine (123I-AIBG), a new sympatho-adrenal imaging agent: comparison with 123I- metaiodobenzylguanidine (123I-MIBG). J. Nucl. Med. 27: 1138-1142.
11. SHULKIN, B.L. et al. 1992. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J. Nucl. Med. 33: 1125-1131.
12. 11C hydroxyephedrine PET. Radiology 230: 423-428.
13. SHULKIN, B.L. et al. 1995. PET epinephrine studies of pheochromocytoma. J. Nucl. Med. 36: 22P-23P.
14. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J. Clin. Endocrinol. Metab. 88: 4083-4087.
15. 18F]-fluorodopamine positron emission tomography with [123In]-metaiodobenzylguanidine and [111In]-pentetreotide scintigraphy in the localization of pheochromocytoma, ENDO. 86th Annual Meeting of the American Endocrine Society, New Orleans, LA, The Endocrine Society: 452-453.
16. 18F DOPA whole body PET - initial results. Radiology 222: 507-512.
17. SHULKIN, B.L. et al. 1999. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212: 35-41.
18. MAMEDE, M. et al. 2005. Discordant localization of [18-F]- fluorodeoxyglucose, in [18-F]-fluorodopamine-negative metastatic pheochromocytoma sites. J. Nucl. Med. 46 (CD-ROM Suppl.): 1324.
19. EZUDDIN, S. et al. 2005. MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy. Clin. Nucl. Med. 30: 579-581.
20. HOFLAND, L.J. et al. 1999. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J. Clin. Endocrinol. Metab. 84: 775-780.
21. REUBI, J.C. et al. 1992. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J. Clin. Endocrinol. Metab. 74: 1082-1089.
22. MUNDSCHENK, J. et al. 2003. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J. Clin. Endocrinol. Metab. 88: 5150-5157.
23. VAN DER HARST, E. et al. 2001. [(123)I]metaiodobenzylguanidine and [(111)In] octreotide uptake in benign and malignant pheochromocytomas. J. Clin. Endocrinol. Metab. 86: 685-693.
24. SCHMIDT, M. et al. 2002. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur. J. Nucl. Med. Mol. Imaging 29: 1571-1580.
25. LAMBERTS, S.W. et al. 1990. Somatostatin-receptor imaging in the localization of endocrine tumors. N. Engl. J. Med. 323: 1246-1249.
26. KRENNING, E.P. et al. 1993. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20: 716-731.
27. TELISCHI, F.F. et al. 2000. Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol. Head Neck Surg. 122: 358-362.
28. DUET, M. et al. 2003. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J. Nucl. Med. 44: 1767-1774.
29. BUSTILLO, A. et al. 2004. Octreotide scintigraphy in the head and neck. Laryngoscope 114: 434-440.
30. BERRY, C.R. et al. 2002. Imaging of pheochromocytoma in 2 dogs using p-[18F] fluorobenzylguanidine. Vet. Radiol. Ultrasound. 43: 183-186.
31. PLACHCINSKA, A. et al. 2003. Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication. Eur. J. Nucl. Med. Mol. Imaging 30: 1402-1406.
32. HOFMANN, M. et al. 2001. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 28: 1751-1757.
33. ANDERSON, C.J. et al. 2001. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med. 42: 213-221.
34. WESTER, H.J. et al. 2003. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur. J. Nucl. Med. Mol. Imaging 30: 117-122.
35. SCHOTTELIUS, M. et al. 2004. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin. Cancer Res. 10: 3593-3606.
36. KOWALSKI, J. et al. 2003. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT: first results in patients with neuroendocrine tumors. Mol. Imaging Biol. 5: 42-48.
37. GABRIEL, M. et al. 2003. An intrapatient comparison of 99mTc-EDDA/HYNICTOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J. Nucl. Med. 44: 708-716.